Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 5/20 | 0.38 |
| ▸ | TSHR | P16473 | 4/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.36 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.35 |
| ▸ | LMNA | P02545 | 5/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | PTBP1 | P26599 | 1/20 | 0.34 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6442095 | 0.95 | CYP2C9 (0.39) | CYP2C9TSHRMAPTKEAP1NFE2L2 | |
| SCHEMBL6439828 | 0.93 | KMT2A (0.39) | CYP2C9TSHRMAPTCYP3A4LMNA | |
| SCHEMBL6438597 | 0.77 | DPP8 (0.43) | LMNAKMT2AALDH1A1 | |
| SCHEMBL4186450 | 0.77 | HTT (0.56) | TSHRKEAP1NFE2L2LMNAKMT2A | |
| SCHEMBL9994204 | 0.75 | ATM (0.47) | MAPTKEAP1NFE2L2LMNAKMT2A | |
| SCHEMBL16587924 | 0.75 | ATM (0.47) | MAPTKEAP1NFE2L2LMNAKMT2A | |
| SCHEMBL7087412 | 0.75 | CTSK (0.51) | MAPT | |
| SCHEMBL6166 | 0.75 | CTSK (0.51) | MAPT | |
| SCHEMBL13363641 | 0.75 | CTSK (0.51) | MAPT | |
| SCHEMBL767076 | 0.75 | CTSK (0.51) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050209177-A9 | Combined therapeutical treatment of hyperproliferative diseases | TOCQUE BRUNO | 2005-09-22 | — | — | US | disclosed |
| US-20040127437-A1 | Combined therapeutical treatment of hyperproliferative diseases | TOCQUE BRUNO (FR) | 2004-07-01 | — | — | US | disclosed |
| US-20010021395-A1 | Method for destroying hyperproliferative cells by combined p53 and taxoid treatment | TOCQUE BRUNO (FR) | 2001-09-13 | — | — | US | disclosed |
| US-6262032-B1 | WHEREIN THE ADENOVIRAL VECTOR AND THE TAXOID COMPOUND ARE BROUGHT INTO CONTACT WITH THE CELL SIMULTANEOUSLY. | AVENTIS PHARMA S.A. (FR) | 2001-07-17 | — | — | US | disclosed |
| US-5670536-A | Pharmaceutical composition based on taxoids | RHONE-POULENC RORER S.A. (FR) | 1997-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010021395-A1 | Method for destroying hyperproliferative cells by combined p53 and taxoid treatment | TP53, HRAS, MYC | CYP2C9 4885/4885TSHR 3397/4885MAPT 3248/4885 |
| US-20050209177-A9 | Combined therapeutical treatment of hyperproliferative diseases | HRAS, MYC, TP53 | CYP2C9 4885/4885TSHR 3604/4885MAPT 3987/4885 |
| US-20040127437-A1 | Combined therapeutical treatment of hyperproliferative diseases | HRAS, MYC, TP53 | CYP2C9 4885/4885TSHR 3604/4885MAPT 3987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.